In 2023, Johnson & Johnson Innovative Medicine provided $42.8 billion in rebates, discounts and fees to various entities within the healthcare system. The distribution included $13.4 billion (31%) to private insurers and pharmacy benefit managers (PBMs), $6.0 billion (14%) to the 340B Program and $5.9 billion (14%) to Medicare.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.